EZH2 and neoplasm: In human and mouse HNSCC, EZH2 inhibitor or CRISPR-mediated EZH2 deficiency enhanced MHC-I expression and antigen presentation on tumor cells, and increased antigen-specific CD8+ T cell proliferation, IFN-γ production, and tumor cell cytotoxicity.